BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 20420512)

  • 1. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
    Yuan S; Shi C; Liu L; Han W
    Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective anti-tumor responses induced by recombinant bacillus Calmette-Guérin vaccines based on different tandem repeats of MUC1 and GM-CSF.
    Yuan S; Shi C; Han W; Ling R; Li N; Wang T
    Eur J Cancer Prev; 2009 Sep; 18(5):416-23. PubMed ID: 19550341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine.
    Chung MA; Luo Y; O'Donnell M; Rodriguez C; Heber W; Sharma S; Chang HR
    Cancer Res; 2003 Mar; 63(6):1280-7. PubMed ID: 12649188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel Bacillus Calmette-Guérin-based breast cancer vaccine that coexpresses multiple tandem repeats of MUC1 and CD80 breaks the immune tolerance and inhibits MUC1-positive breast cancer growth.
    Yuan S; Shi C; Lv Y; Wang T; Wang H; Han W
    Cancer Biother Radiopharm; 2009 Oct; 24(5):607-13. PubMed ID: 19877891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with two recombinant Bacillus Calmette-Guérin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice.
    Yuan S; Shi C; Ling R; Wang T; Wang H; Han W
    J Cancer Res Clin Oncol; 2010 Sep; 136(9):1359-67. PubMed ID: 20127358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC1 as a target antigen for cancer immunotherapy.
    Acres B; Limacher JM
    Expert Rev Vaccines; 2005 Aug; 4(4):493-502. PubMed ID: 16117706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MUC1 and breast cancer.
    Apostolopoulos V; Pietersz GA; McKenzie IF
    Curr Opin Mol Ther; 1999 Feb; 1(1):98-103. PubMed ID: 11249691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2.
    He J; Shen D; O'Donnell MA; Chang HR
    Int J Oncol; 2002 Jun; 20(6):1305-11. PubMed ID: 12012014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
    Yu DS; Lee CF; Hsieh DS; Chang SY
    Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
    Acres B
    J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy.
    Lee CF; Chang SY; Hsieh DS; Yu DS
    Cancer Gene Ther; 2004 Mar; 11(3):194-207. PubMed ID: 14973549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
    Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Sawai S; Inoue S; Abe H; Hanasawa K; Fujino S
    Int J Mol Med; 2003 Oct; 12(4):493-502. PubMed ID: 12964025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunotherapeutic effects of recombinant Bacillus Calmette-Guérin resistant to antimicrobial peptides on bladder cancer cells.
    Cho MJ; Kim MJ; Kim K; Choi YW; Lee SJ; Whang YM; Chang IH
    Biochem Biophys Res Commun; 2019 Jan; 509(1):167-174. PubMed ID: 30579607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective immunity elicited by rBCG vaccines.
    Stover CK; Bansal GP; Langerman S; Hanson MS
    Dev Biol Stand; 1994; 82():163-70. PubMed ID: 7958471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
    Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
    Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.
    Lee CF; Chang SY; Hsieh DS; Yu DS
    J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
    Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
    Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges.
    Joseph J; Saubi N; Pezzat E; Gatell JM
    Expert Rev Vaccines; 2006 Dec; 5(6):827-38. PubMed ID: 17184220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies used for MUC1 immunotherapy: human clinical studies.
    Tang CK; Katsara M; Apostolopoulos V
    Expert Rev Vaccines; 2008 Sep; 7(7):963-75. PubMed ID: 18767946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.
    Gjerstorff MF; Burns J; Ditzel HJ
    Expert Opin Biol Ther; 2010 Jul; 10(7):1061-75. PubMed ID: 20420535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.